GeneDx Holdings Corp. (WGS) Stock Analysis & Investment Frameworks
GeneDx Holdings Corp. (WGS) stock analysis on Invetso. Review GeneDx Holdings Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
GeneDx Holdings Corp. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
GeneDx Holdings Corp. Key Financial Metrics
- Market Cap: $2.06B
- Revenue: $427.54M
- ROE: -38.72%
- ROIC: -14.69%
- Dividend Yield: N/A
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp. Investment Frameworks
Invetso analyzes GeneDx Holdings Corp. (WGS) across the following frameworks:
- GeneDx Holdings Corp. 10Y Growth Potential
- GeneDx Holdings Corp. Scenario Analysis
- GeneDx Holdings Corp. Risks & Opportunities
- GeneDx Holdings Corp. Economic Moat
- GeneDx Holdings Corp. Business Model
- GeneDx Holdings Corp. Management
- GeneDx Holdings Corp. SWOT Analysis
- GeneDx Holdings Corp. Porter's 5 Forces
- GeneDx Holdings Corp. PESTLE Analysis
- GeneDx Holdings Corp. ESG Analysis